ADAM17 and serum lipopolysaccharide activity: Inhibition of ADAM17 as well as global or myeloid cell-restricted deletion of ADAM17 in mice results in reduced systemic TNF-α levels following LPS treatment and protects mice from fatal endotoxemia [5, 6, 7].